Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68GaNOTA-Anti-MMR-VHH2 PET Imaging in NSCLC
NCT05933239Phase 2Recruiting
- Sponsor
- UZ Brussel
- Start
- Mar 2023
- Primary completion
- Apr 2027
- Modality
- Nanobodies (VHH)
- Countries
- 1
01
Overview
A Phase 2 trial of 68Ga-NOTA-anti-MMR VHH2 in non-small cell lung cancer (NSCLC), sponsored by UZ Brussel. Started Mar 2023; status: recruiting.
02
Drugs
68Ga-NOTA-anti-MMR VHH2
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05933239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05933239.